Elekta B Shs (EKTAF) 7.4800 $EKTAF Elekta repor
Post# of 273376
Posted On: 06/09/2016 7:04:21 AM
Elekta B Shs (EKTAF) 7.4800 $EKTAF
Elekta reports increase in shares during January 2016
M2 - Mon Feb 01, 6:13AM CST
Human care company Elekta AB (STO:EKTAB) reported on Friday an increase of 65 new B-shares in the company during January 2016.
Clinical IT Systems Pipeline Review, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr9wlk/clinical_it) has announced the addition of the "Clinical IT Systems - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Clinical IT Systems pipeline products. Key Topics Covered: - Extensive coverage of the Clinical IT Systems under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Clinical IT Systems and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Clinical IT Systems under development - Develop market-entry and market expansion strategies Companies Mentioned: - Accuray Incorporated - Agfa HealthCare NV - AirStrip Technologies, Inc. - AlgorithmRx, LLC - Auckland University of Technology - Beckman Coulter, Inc. - City University London - Diabetes Tools Sweden AB - Elekta AB - H. Lee Moffitt Cancer Center & Research Institute, Inc. - Haemonetics Corporation - Imaxdi. - Medical Interactive Technologies Ltd. - MediLogos Ltd. - Ohio University - Ortoma AB - Predictive Medical Technologies, Inc. - Roche Diagnostics International Ltd. - Therapeutic Monitoring Systems (TMS) Inc. - University of Arkansas - University of California, San Diego - University of Canterbury - Washington University in St. Louis Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Clinical IT Systems - Pipeline Products under Development by Companies 5 Clinical IT Systems Companies and Product Overview 6 Clinical IT Systems- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/kr...linical_it
HAE: 29.44 (+0.36), ARAY: 5.67 (+0.06)
Elekta posts net income of SEK189m in Q2 2015/16
M2 - Fri Dec 04, 7:04AM CST
Human care company Elekta AB (STO:EKTAB.ST) on Friday reported net income of SEK189m, or diluted EPS of SEK0.49, for the second quarter of 2015/16, from May 2015 to October 2015.
Global Market Study on Neurosurgical Products 2015-2020: Market is Anticipated to Grow to US$7,756.2 Mn by 2022
M2 - Tue Nov 10, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/6q83k8/global_market) has announced the addition of the "Global Market Study on Neurosurgical Products: Asia Pacific to Witness Highest Growth by 2022" report to their offering. The neurosurgical products market is anticipated to grow from an estimated US$3,685.8 Mn by the end of 2015 to US$7,756.2 Mn by 2022at a CAGR of 11.2% during the forecast period. The global neurosurgical products market is witnessing significant growth due to growing geriatric population. Moreover, increasing the incidence of brain tumors, growing government funding, and raising awareness about neurosurgical disorders are also driving the growth of the market. Furthermore, growing demand for minimally invasive surgeries is expected to create growth opportunities for the neurosurgical products market. However, stringent regulatory requirements, long approval times for new neurosurgical products, and availability of alternative treatment for neurosurgical diseases inhibit the growth of the market. North America is projected to be the largest market for neurosurgical products, with an aneurysm being the most prevalent neurosurgical condition, and embolization products being the most preferred neurosurgical product by the end of 2015. Asia Pacific is expected to be the fastest-growing region in terms of revenue while stereotactic radiosurgery is projected to be the fastest-growing neurosurgical product type segment over the forecast period. Aneurysms are abnormal widening or bulging of parts of blood vessels due to weakening of the wall of the blood vessel.The global aneurysms segment is expected to grow from an estimated US$1,328.8 Mn by the end of2015 to US$2,866.1 Mn by 2022 at a CAGR of 11.6% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Condition Chapter 7 Market Size and Forecast by Procedure Chapter 8 Market Size and Forecast by Product Type Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - B. Braun Melsungen AG - Elekta AB - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - KARL STORZ GmbH & Co. KG. - Medtronic plc - Penumbra, Inc. - Stryker Corporation - Terumo Corporation - Varian Medical Systems, Inc. For more information visit http://www.researchandmarkets.com/research/6q...bal_market
JNJ: 115.80 (+0.07), VAR: 85.52 (+1.00), MDT: 84.79 (+1.07), IARTV: 65.00 (-37.45), PEN: 60.75 (+1.24), SYK: 114.29 (+1.70)
Elekta names members of Nomination Committee for 2016 AGM
M2 - Tue Nov 03, 6:18AM CST
Elekta AB (STO: EKTAB.ST) announcedon Tuesday that the members of its nomination committee for 2016 Annual General Meeting are Laurent Leksell, in his capacity as chairman of the board of directors of Elekta and representing his own and related parties' holdings; Asa Nisell, appointed by Swedbank Robur funds; Per Colleen, appointed by the Fourth Swedish National Pension Fund; John Hernander, appointed by Nordea Investment funds and Mikael Wiberg, appointed by Alecta
Brain Monitoring Devices Market 2014-2020 - Global Strategic Business Report 2015
M2 - Wed Oct 21, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fksxww/brain_monitoring) has announced the addition of the "Brain Monitoring Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brain Monitoring Devices in US$. The Global market is further analyzed by the following Product Segments: IntraCranial Pressure (ICP) Monitors, Electroencephalography (EEG) Devices, Magnetoencephalography (MEG) Devices, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as - Advanced Brain Monitoring, Inc. (US) - Cadwell Laboratories, Inc. (US) - CAS Medical Systems (US) - Compumedics, Ltd. (Australia) - Compumedics Germany GmbH (Germany) - DePuy Synthes Companies (US) - Elekta AB (Sweden) - Electrical Geodesics, Inc. (US) - HeadSense Medical, Inc. (US) - Integra Life Sciences Corporation (US) - Masimo Corporation (US) - Medtronic, Plc. (Ireland) - MEG International Services Ltd. (Canada) - Natus Medical Incorporated (US) - NeuroWave Systems, Inc. (US) - Nihon Kohden Corporation (Japan) - Nonin Medical, Inc. (US) - Ornim Medical (Israel) - Rimed, Inc. (US) - Spiegelberg GmbH (Germany) - Third Eye Diagnostics, Inc. (US) - Vittamed Corporation (US) - Yokogawa Electric Corporation (Japan) Key Topics Covered: 1. Industry Overview 2. EEG - The Largest Brain Monitoring Devices Segment 3. A Focus On Other Brain Monitoring Devices 4. Competitive Landscape 5. Market Trends, Issues & Drivers 6. Product Overview 7. Product Introductions/Innovations 8. Recent Industry Activity 9. Focus On Select Major Players 10. Global Market Perspective Total Companies Profiled: 38 (including Divisions/Subsidiaries - 41) - The United States (20) - Canada (1) - Japan (2) - Europe (12) - - France (2) - - Germany (3) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (4) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/fk...monitoring
BABY: 35.27 (-0.07), MASI: 52.14 (+0.57), MDT: 84.79 (+1.07), CASM: 1.87 (-0.02)
Elekta's new Leksell Gamma Knife Icon brain radiosurgery system acquired by seven US hospitals
M2 - Mon Oct 12, 6:11AM CDT
Elekta AB (STO:EKTAB.ST) announced on Monday that seven medical centres in the US are the first in the nation to order Leksell Gamma Knife Icon, which features the first integrated stereotactic cone beam CT imaging, online adaptive dose evaluation and planning enabling the most accurate delivery of frameless and frame-based treatments.
Gamma Knife Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025
M2 - Fri Sep 04, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7wf6l/gamma_knife) has announced the addition of the "Gamma Knife Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025" report to their offering. This report examines the Global Gamma Knife' market for the period 2012-2025. The primary objective of the report is to offer updates on the advancement of Gamma Knife, examining the marketing efforts and business strategies undertaken by the manufacturing companies which is significantly transforming the Stereotactic Radiosurgery market. This study analyses, estimates and forecasts the global Gamma Knife market from the demand as well as supply perspective, in terms of revenue (US$ Mn) during the forecast period 2015 to 2025. The report also highlights the impact of various drivers and restraints in various regions along with their impact during the forecast period. The report starts with an overview of Gamma Knifein treatment in various indications such as Brain Metastasis, Cancer, Arteriovenous Malformation (AVM), Trigeminal Neuralgia and Others. For example, Cobalt-60 radioactive isotope is increasingly being used for the treatment of brain tumours and cancers in order to increase life expectancy. Moreover, market expansion and innovation in techniques as well as development of novel applications in Stereotactic Radiosurgery are further driving Gamma Knife market growth. Due to these reasons, Gamma Knife market is expected to have a significant demand in the near future. There are five major types of Gamma Knife indications which have been covered in this report: Brain Metastasis, Cancer, Arteriovenous Malformation (AVM), Trigeminal Neuralgia and Others. Brain Metastasis treatment contribute around 68.5% share of the global Gamma Knife value in 2014, Brain Metastasis is anticipated to witness a CAGR of 9.2% during the forecast period. Considering the type of body part treated with Gamma Knife, the global Gamma Knife market is segmented into: Head, Neck and Other body parts. Among the aforementioned segments, Head treatment with Gamma Knife is expected to dominate the global market with over 88.1% market value share throughout the forecast period. The global head treatment with Gamma Knife accounted for US$ 139.8 Mn in 2014, and is anticipated to reach a value of US$ 364.8 Mn by 2025, growing at a CAGR of 9.2% during the forecast period. Moreover, the scope of Gamma Knife treatment in other indications is expected to expand in the future too, due to market expansion and innovation in techniques. This section analysis each indications in terms of market revenue. Key Topics Covered: 1. Research Methodology 2. Assumptions & Acronyms Used 3. Executive Summary 4. Gamma Knife Market Overview 5. Gamma Knife Market Analysis and Forecast By Disease Indication 6. Gamma Knife Market Analysis and Forecast By Anatomy 7. Gamma Knife Market Analysis and Forecast By Geography 8. Competitive Landscape - Elekta AB - Huiheng Medical, Inc. - Varian Medical Systems, Inc. For more information visit http://www.researchandmarkets.com/research/t7...amma_knife
VAR: 85.52 (+1.00)
Elekta reduces loss in May to July 2015/16
M2 - Tue Sep 01, 12:09PM CDT
Elekta AB (STO: EKTAB.ST) on Monday reported a negative net income of SEK129m, or SEK0.34 per diluted share, for the quarter May 2015 to July 2015.
Bulletin from Elekta's Annual General Meeting 2015
BusinessWire - Tue Sep 01, 9:31AM CDT
Regulatory News:
Elekta's Versa HD selected by Gustave Roussy cancer centre
M2 - Tue Sep 01, 8:15AM CDT
Elekta AB (STO:EKTAB.ST) announced on Monday that it has received an order for four Versa HD linear accelerators from Gustave Roussy, an European comprehensive cancer centre, replacing the customer's existing installed base of competing systems.
Welcome to the Annual General Meeting of Shareholders of Elekta AB (publ)
BusinessWire - Mon Aug 03, 1:03AM CDT
Regulatory News:
Elekta reports proposals by nomination committee on board of directors for AGM 2015
M2 - Wed Jul 01, 6:01AM CDT
Human care company Elekta AB (STO:EKTA-B.ST) announced today that the nomination committee of its board of directors has proposed that the 2015 Annual General Meeting re-elect board members Laurent Leksell, Luciano Cattani, Siaou-Sze Lien, Wolfgang Reim, Jan Secher, Birgitta Stymne Goransson and Tomas Puusepp.
Elekta reports increase in shares during January 2016
M2 - Mon Feb 01, 6:13AM CST
Human care company Elekta AB (STO:EKTAB) reported on Friday an increase of 65 new B-shares in the company during January 2016.
Clinical IT Systems Pipeline Review, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr9wlk/clinical_it) has announced the addition of the "Clinical IT Systems - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Clinical IT Systems pipeline products. Key Topics Covered: - Extensive coverage of the Clinical IT Systems under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Clinical IT Systems and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Clinical IT Systems under development - Develop market-entry and market expansion strategies Companies Mentioned: - Accuray Incorporated - Agfa HealthCare NV - AirStrip Technologies, Inc. - AlgorithmRx, LLC - Auckland University of Technology - Beckman Coulter, Inc. - City University London - Diabetes Tools Sweden AB - Elekta AB - H. Lee Moffitt Cancer Center & Research Institute, Inc. - Haemonetics Corporation - Imaxdi. - Medical Interactive Technologies Ltd. - MediLogos Ltd. - Ohio University - Ortoma AB - Predictive Medical Technologies, Inc. - Roche Diagnostics International Ltd. - Therapeutic Monitoring Systems (TMS) Inc. - University of Arkansas - University of California, San Diego - University of Canterbury - Washington University in St. Louis Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Clinical IT Systems - Pipeline Products under Development by Companies 5 Clinical IT Systems Companies and Product Overview 6 Clinical IT Systems- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/kr...linical_it
HAE: 29.44 (+0.36), ARAY: 5.67 (+0.06)
Elekta posts net income of SEK189m in Q2 2015/16
M2 - Fri Dec 04, 7:04AM CST
Human care company Elekta AB (STO:EKTAB.ST) on Friday reported net income of SEK189m, or diluted EPS of SEK0.49, for the second quarter of 2015/16, from May 2015 to October 2015.
Global Market Study on Neurosurgical Products 2015-2020: Market is Anticipated to Grow to US$7,756.2 Mn by 2022
M2 - Tue Nov 10, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/6q83k8/global_market) has announced the addition of the "Global Market Study on Neurosurgical Products: Asia Pacific to Witness Highest Growth by 2022" report to their offering. The neurosurgical products market is anticipated to grow from an estimated US$3,685.8 Mn by the end of 2015 to US$7,756.2 Mn by 2022at a CAGR of 11.2% during the forecast period. The global neurosurgical products market is witnessing significant growth due to growing geriatric population. Moreover, increasing the incidence of brain tumors, growing government funding, and raising awareness about neurosurgical disorders are also driving the growth of the market. Furthermore, growing demand for minimally invasive surgeries is expected to create growth opportunities for the neurosurgical products market. However, stringent regulatory requirements, long approval times for new neurosurgical products, and availability of alternative treatment for neurosurgical diseases inhibit the growth of the market. North America is projected to be the largest market for neurosurgical products, with an aneurysm being the most prevalent neurosurgical condition, and embolization products being the most preferred neurosurgical product by the end of 2015. Asia Pacific is expected to be the fastest-growing region in terms of revenue while stereotactic radiosurgery is projected to be the fastest-growing neurosurgical product type segment over the forecast period. Aneurysms are abnormal widening or bulging of parts of blood vessels due to weakening of the wall of the blood vessel.The global aneurysms segment is expected to grow from an estimated US$1,328.8 Mn by the end of2015 to US$2,866.1 Mn by 2022 at a CAGR of 11.6% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Condition Chapter 7 Market Size and Forecast by Procedure Chapter 8 Market Size and Forecast by Product Type Chapter 9 Market Size and Forecast by Geography Chapter 10 Competitive Scenario Chapter 11 Company Profiles - B. Braun Melsungen AG - Elekta AB - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - KARL STORZ GmbH & Co. KG. - Medtronic plc - Penumbra, Inc. - Stryker Corporation - Terumo Corporation - Varian Medical Systems, Inc. For more information visit http://www.researchandmarkets.com/research/6q...bal_market
JNJ: 115.80 (+0.07), VAR: 85.52 (+1.00), MDT: 84.79 (+1.07), IARTV: 65.00 (-37.45), PEN: 60.75 (+1.24), SYK: 114.29 (+1.70)
Elekta names members of Nomination Committee for 2016 AGM
M2 - Tue Nov 03, 6:18AM CST
Elekta AB (STO: EKTAB.ST) announcedon Tuesday that the members of its nomination committee for 2016 Annual General Meeting are Laurent Leksell, in his capacity as chairman of the board of directors of Elekta and representing his own and related parties' holdings; Asa Nisell, appointed by Swedbank Robur funds; Per Colleen, appointed by the Fourth Swedish National Pension Fund; John Hernander, appointed by Nordea Investment funds and Mikael Wiberg, appointed by Alecta
Brain Monitoring Devices Market 2014-2020 - Global Strategic Business Report 2015
M2 - Wed Oct 21, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fksxww/brain_monitoring) has announced the addition of the "Brain Monitoring Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brain Monitoring Devices in US$. The Global market is further analyzed by the following Product Segments: IntraCranial Pressure (ICP) Monitors, Electroencephalography (EEG) Devices, Magnetoencephalography (MEG) Devices, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as - Advanced Brain Monitoring, Inc. (US) - Cadwell Laboratories, Inc. (US) - CAS Medical Systems (US) - Compumedics, Ltd. (Australia) - Compumedics Germany GmbH (Germany) - DePuy Synthes Companies (US) - Elekta AB (Sweden) - Electrical Geodesics, Inc. (US) - HeadSense Medical, Inc. (US) - Integra Life Sciences Corporation (US) - Masimo Corporation (US) - Medtronic, Plc. (Ireland) - MEG International Services Ltd. (Canada) - Natus Medical Incorporated (US) - NeuroWave Systems, Inc. (US) - Nihon Kohden Corporation (Japan) - Nonin Medical, Inc. (US) - Ornim Medical (Israel) - Rimed, Inc. (US) - Spiegelberg GmbH (Germany) - Third Eye Diagnostics, Inc. (US) - Vittamed Corporation (US) - Yokogawa Electric Corporation (Japan) Key Topics Covered: 1. Industry Overview 2. EEG - The Largest Brain Monitoring Devices Segment 3. A Focus On Other Brain Monitoring Devices 4. Competitive Landscape 5. Market Trends, Issues & Drivers 6. Product Overview 7. Product Introductions/Innovations 8. Recent Industry Activity 9. Focus On Select Major Players 10. Global Market Perspective Total Companies Profiled: 38 (including Divisions/Subsidiaries - 41) - The United States (20) - Canada (1) - Japan (2) - Europe (12) - - France (2) - - Germany (3) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (4) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/fk...monitoring
BABY: 35.27 (-0.07), MASI: 52.14 (+0.57), MDT: 84.79 (+1.07), CASM: 1.87 (-0.02)
Elekta's new Leksell Gamma Knife Icon brain radiosurgery system acquired by seven US hospitals
M2 - Mon Oct 12, 6:11AM CDT
Elekta AB (STO:EKTAB.ST) announced on Monday that seven medical centres in the US are the first in the nation to order Leksell Gamma Knife Icon, which features the first integrated stereotactic cone beam CT imaging, online adaptive dose evaluation and planning enabling the most accurate delivery of frameless and frame-based treatments.
Gamma Knife Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025
M2 - Fri Sep 04, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7wf6l/gamma_knife) has announced the addition of the "Gamma Knife Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025" report to their offering. This report examines the Global Gamma Knife' market for the period 2012-2025. The primary objective of the report is to offer updates on the advancement of Gamma Knife, examining the marketing efforts and business strategies undertaken by the manufacturing companies which is significantly transforming the Stereotactic Radiosurgery market. This study analyses, estimates and forecasts the global Gamma Knife market from the demand as well as supply perspective, in terms of revenue (US$ Mn) during the forecast period 2015 to 2025. The report also highlights the impact of various drivers and restraints in various regions along with their impact during the forecast period. The report starts with an overview of Gamma Knifein treatment in various indications such as Brain Metastasis, Cancer, Arteriovenous Malformation (AVM), Trigeminal Neuralgia and Others. For example, Cobalt-60 radioactive isotope is increasingly being used for the treatment of brain tumours and cancers in order to increase life expectancy. Moreover, market expansion and innovation in techniques as well as development of novel applications in Stereotactic Radiosurgery are further driving Gamma Knife market growth. Due to these reasons, Gamma Knife market is expected to have a significant demand in the near future. There are five major types of Gamma Knife indications which have been covered in this report: Brain Metastasis, Cancer, Arteriovenous Malformation (AVM), Trigeminal Neuralgia and Others. Brain Metastasis treatment contribute around 68.5% share of the global Gamma Knife value in 2014, Brain Metastasis is anticipated to witness a CAGR of 9.2% during the forecast period. Considering the type of body part treated with Gamma Knife, the global Gamma Knife market is segmented into: Head, Neck and Other body parts. Among the aforementioned segments, Head treatment with Gamma Knife is expected to dominate the global market with over 88.1% market value share throughout the forecast period. The global head treatment with Gamma Knife accounted for US$ 139.8 Mn in 2014, and is anticipated to reach a value of US$ 364.8 Mn by 2025, growing at a CAGR of 9.2% during the forecast period. Moreover, the scope of Gamma Knife treatment in other indications is expected to expand in the future too, due to market expansion and innovation in techniques. This section analysis each indications in terms of market revenue. Key Topics Covered: 1. Research Methodology 2. Assumptions & Acronyms Used 3. Executive Summary 4. Gamma Knife Market Overview 5. Gamma Knife Market Analysis and Forecast By Disease Indication 6. Gamma Knife Market Analysis and Forecast By Anatomy 7. Gamma Knife Market Analysis and Forecast By Geography 8. Competitive Landscape - Elekta AB - Huiheng Medical, Inc. - Varian Medical Systems, Inc. For more information visit http://www.researchandmarkets.com/research/t7...amma_knife
VAR: 85.52 (+1.00)
Elekta reduces loss in May to July 2015/16
M2 - Tue Sep 01, 12:09PM CDT
Elekta AB (STO: EKTAB.ST) on Monday reported a negative net income of SEK129m, or SEK0.34 per diluted share, for the quarter May 2015 to July 2015.
Bulletin from Elekta's Annual General Meeting 2015
BusinessWire - Tue Sep 01, 9:31AM CDT
Regulatory News:
Elekta's Versa HD selected by Gustave Roussy cancer centre
M2 - Tue Sep 01, 8:15AM CDT
Elekta AB (STO:EKTAB.ST) announced on Monday that it has received an order for four Versa HD linear accelerators from Gustave Roussy, an European comprehensive cancer centre, replacing the customer's existing installed base of competing systems.
Welcome to the Annual General Meeting of Shareholders of Elekta AB (publ)
BusinessWire - Mon Aug 03, 1:03AM CDT
Regulatory News:
Elekta reports proposals by nomination committee on board of directors for AGM 2015
M2 - Wed Jul 01, 6:01AM CDT
Human care company Elekta AB (STO:EKTA-B.ST) announced today that the nomination committee of its board of directors has proposed that the 2015 Annual General Meeting re-elect board members Laurent Leksell, Luciano Cattani, Siaou-Sze Lien, Wolfgang Reim, Jan Secher, Birgitta Stymne Goransson and Tomas Puusepp.
(0)
(0)